As a result, Sotorasib and Adagrasib are now included in the NCCN (National Comprehensive Cancer Network) guidelines for treating locally advanced and metastatic pancreatic ductal adenocarcinoma (mPDAC) with KRAS-G12C mutations. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.